GFAP and Alzheimer disease: Pereira et al. reported that cerebrospinal fluid (CSF) and plasma GFAP were predictors of longitudinal cognitive deterioration in the whole cohort, comprising AD patients, even after correction for longitudinal amyloid-β positron emission tomography (Aβ-PET) changes [15].